Glucose metabolism and NRF2 coordinate the antioxidant response in melanoma resistant to MAPK inhibitors

Targeted therapies as BRAF and MEK inhibitor combination have been approved as first-line treatment for BRAF-mutant melanoma. However, disease progression occurs in most of the patients within few months of therapy. Metabolic adaptations have been described in the context of acquired resistance to B...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cell Death Dis
Main Authors: Khamari, Raeeka, Trinh, Anne, Gabert, Pierre Elliott, Corazao-Rozas, Paola, Riveros-Cruz, Samuel, Balayssac, Stephane, Malet-Martino, Myriam, Dekiouk, Salim, Joncquel Chevalier Curt, Marie, Maboudou, Patrice, Garçon, Guillaume, Ravasi, Laura, Guerreschi, Pierre, Mortier, Laurent, Quesnel, Bruno, Marchetti, Philippe, Kluza, Jerome
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5832419/
https://ncbi.nlm.nih.gov/pubmed/29487283
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-018-0340-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados